Merck’s KEYTRUDA® (pembrolizumab) showed a complete response rate of nearly 40 percent
Merck announced results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease. October 20, 2018